The CMA Phase 1 decision is a procedural step; the key question is whether the proposed remedy will satisfy the CMA in Phase 2. Monitor for the CMA's Phase 2 decision and any conditions imposed. The merger timeline to early 2027 remains intact.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $23.19entry
- T+1 · 4d ago −0.04%α +0.32% · $23.18
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
AkzoNobel and Axalta are considering the UK CMA's Phase 1 decision on their proposed merger, which identified competition concerns only in UK vehicle refinish coatings. The companies plan to address this with the same remedy package already agreed with the European Commission, involving divestment of AkzoNobel's European VR coatings business. The merger is expected to close by early 2027, creating a combined company with approximately $17 billion in revenue.
Key Facts
- UK CMA Phase 1 decision identified competition concerns solely in UK vehicle refinish coatings
- AkzoNobel and Axalta will propose the same remedy as agreed with the European Commission: divestment of AkzoNobel's European VR coatings business including UK
- Companies remain confident the merger will complete by early 2027
- Combined company would have approximately $17 billion in revenue
Financial Impact
No financial terms disclosed; merger consideration was set in prior filings (June 2026). The remedy involves divestment of a business unit, but no value stated.
Risk Factors
- CMA may not accept the proposed remedy in Phase 2, potentially requiring additional divestitures or blocking the merger
- Merger completion could be delayed beyond early 2027 if regulatory hurdles arise
- The divestment of the European VR coatings business may reduce combined revenue and synergies
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-017304 |
| Document: dp256705_6k.htm | 0000950103-26-017304 |
| Document: 0000950103-26-017304-index-headers.html | 0000950103-26-017304 |
| Document: 0000950103-26-017304-index.html | 0000950103-26-017304 |
| Document: 0000950103-26-017304.txt | 0000950103-26-017304 |
| Earnings Context (Synthetic; results releases only) | 0000950103-26-017304 |
Track record
14 reports on AKZOY
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +7.29% at T+20 after the Oct 5, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 4/10 Viewing Entry $23.19 to $23.18 Now $22.90 −1.25% ▼ −0.04% +0.32% vs SPY
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $23.30 to $23.97 Now $22.90 −1.72% ▲ +2.88% +0.51% vs SPY
- Oct 21, 202626d ago 6-K Neutral 5/10 No price data
- Oct 21, 202626d ago 6-K Neutral 4/10 No price data
- Oct 21, 202626d ago 6-K Neutral 4/10 Entry $22.83 to $22.59 Now $22.90 +0.31% ▼ −1.05% +0.13% vs SPY
- Oct 16, 20264w ago 6-K Neutral 4/10 Entry $22.03 to $21.95 Now $22.90 +3.95% ▼ −0.36% −0.79% vs SPY
- Oct 15, 20264w ago 6-K Neutral 3/10 Entry $22.03 to $21.95 Now $22.90 +3.95% ▼ −0.36% −0.79% vs SPY
- Oct 5, 20266w ago 6-K Bullish 6/10 Entry $21.53 to $21.87 Now $22.90 +6.36% ▲ +1.58% +1.03% vs SPY
- Aug 31, 202611w ago 6-K Neutral 3/10 Entry $23.91 to $23.07 Now $22.90 −4.22% ▼ −3.51% −2.83% vs SPY
- Jul 23, 202616w ago 6-K Neutral 3/10 Entry $21.28 to $21.93 Now $22.90 +7.61% ▲ +3.05% +2.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers